Cell Therapeutics says that a review of early- and mid-stage data on its cancer drug candidate pixantrone suggests it is a promising treatment for non-Hodgkin's lymphoma.
According to a summary of peer-reviewed publications in the May edition of Future Oncology, there were five Phase I/II studies in which pixantrone was added to standard chemotherapy regimens for treating relapsed aggressive and indolent NHL. The drug produced encouragingly high rates of overall response (58%-74%) including complete responses (37%-57%). As previously reported, neutropenia was the dose limiting toxicity when used as a single agent.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze